Slingshot members are tracking this event:

Three more Phase 3 clinical trials of ABT-494 will begin enrollment in early 2016 and will include patients with an inadequate response to biologics and patients who are MTX-naive

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
ABBV Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 19, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Clinical Trials, Abt-494, Mtx-naive